###begin article-title 0
###xml 32 37 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts
###end article-title 0
###begin p 1
Current address: Division of Virology, National Institute for Medical Research, London, United Kingdom
###end p 1
###begin p 2
Conceived and designed the experiments: KNB EYK SMW MHM. Performed the experiments: KNB MV. Analyzed the data: KNB MV MHM. Contributed reagents/materials/analysis tools: KNB. Wrote the paper: KNB MHM.
###end p 2
###begin p 3
###xml 83 88 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 238 243 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 557 562 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 853 858 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G (A3G) is a host cytidine deaminase that, in the absence of Vif, restricts HIV-1 replication and reduces the amount of viral DNA that accumulates in cells. Initial studies determined that A3G induces extensive mutation of nascent HIV-1 cDNA during reverse transcription. It has been proposed that this triggers the degradation of the viral DNA, but there is now mounting evidence that this mechanism may not be correct. Here, we use a natural endogenous reverse transcriptase assay to show that, in cell-free virus particles, A3G is able to inhibit HIV-1 cDNA accumulation not only in the absence of hypermutation but also without the apparent need for any target cell factors. We find that although reverse transcription initiates in the presence of A3G, elongation of the cDNA product is impeded. These data support the model that A3G reduces HIV-1 cDNA levels by inhibiting synthesis rather than by inducing degradation.
###end p 3
###begin title 4
Author Summary
###end title 4
###begin p 5
###xml 104 109 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 530 535 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC proteins are cell-encoded factors that inhibit the replication of numerous retroviruses, such as HIV-1, and retrotransposons. In many cases, inhibition is clearly associated with cytidine-to-uridine editing of viral or transposon DNA. On the other hand, a number of studies with particular APOBEC protein/substrate combinations, or engineered proteins that are editing-deficient, have indicated that inhibitory mechanism(s) distinct from editing are also operative. Here, we have analyzed the effects of APOBEC3G, a potent HIV-1 inhibitor, on viral reverse transcription using cell-free viruses (natural endogenous reverse transcriptase assays). We report that APOBEC3G inhibits viral DNA synthesis in a dose-dependent fashion, and does not require editing capabilities to do so. Because the addition of the first nucleotide to the tRNA primer is unaffected by A3G and the magnitude of inhibition increases as later reverse transcription intermediates are measured, we suggest that APOBEC3G acts by impeding the translocation of the reverse transcriptase enzyme along its RNA template, perhaps by binding directly to the RNA. These results provide novel insight into the biological activities of this class of host anti-viral proteins.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 169 172 169 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Sheehy1">[1]</xref>
###xml 337 340 337 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Chiu1">[2]</xref>
###xml 341 344 341 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Malim1">[4]</xref>
###xml 124 129 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G (A3G) is a potent anti-viral polynucleotide cytidine deaminase, initially identified as the cellular target of the HIV-1 viral infectivity factor (Vif) protein [1]. Since this discovery, many APOBEC proteins from various species have been shown to inhibit the replication of a diverse range of viruses and retrotransposons (see [2]-[4] for reviews). However, the exact mechanism(s) by which APOBEC proteins elicit these effects is unresolved, enduringly controversial, and may differ among APOBEC family members.
###end p 7
###begin p 8
###xml 141 144 141 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Sheehy2">[5]</xref>
###xml 145 148 145 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Yu1">[9]</xref>
###xml 294 298 294 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Harris1">[10]</xref>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Zhang1">[12]</xref>
###xml 836 840 836 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Mangeat1">[11]</xref>
###xml 842 846 842 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Bishop1">[13]</xref>
###xml 847 851 847 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Luo1">[20]</xref>
###xml 11 16 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 71 76 <span type="species:ncbi:9606">human</span>
###xml 125 130 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Studies on HIV-1 have revealed that in the absence of the Vif protein, human A3G from virus-producing cells is packaged into HIV-1 particles [5]-[9]. Two phenotypes are then observed when these particles infect new target cells: first, nascent viral reverse transcripts are extensively mutated [10]-[12]. Most of the mutations detected are G-to-A changes in the positive sense, coding strand, implying that deamination of cytidines must occur predominantly on the negative sense strand of cDNA. This, in turn, locates A3G to the site and time of reverse transcription. The fixation of such hypermutation in proviral sequences would presumably lead to the expression of inactive or truncated viral proteins, producing non-infectious virions. The second observed phenotype is a reduction in the accumulation of viral cDNA in target cells [11], [13]-[20]. This could occur either by triggering degradation of reverse transcripts or by inhibiting DNA synthesis.
###end p 8
###begin p 9
###xml 92 96 92 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Harris1">[10]</xref>
###xml 97 101 97 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Mangeat1">[11]</xref>
###xml 637 641 637 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Kaiser1">[16]</xref>
###xml 642 646 642 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Mbisa1">[17]</xref>
###xml 647 651 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Langlois1">[21]</xref>
###xml 794 797 794 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Holmes1">[3]</xref>
###xml 939 943 939 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Chen1">[22]</xref>
###xml 944 948 944 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Turelli1">[24]</xref>
###xml 1062 1066 1062 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Chiu2">[25]</xref>
###xml 1174 1178 1174 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Bishop1">[13]</xref>
###xml 1179 1183 1179 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Langlois1">[21]</xref>
###xml 1331 1335 1331 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Holmes2">[14]</xref>
###xml 1336 1340 1336 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Okeoma1">[23]</xref>
###xml 1341 1345 1341 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Turelli1">[24]</xref>
###xml 1346 1350 1346 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Bogerd2">[26]</xref>
###xml 1351 1355 1351 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Newman1">[27]</xref>
###xml 857 861 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 863 866 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 1014 1019 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1100 1105 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1265 1270 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1272 1276 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1278 1281 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
We, and others, initially proposed a mechanism that linked hypermutation to DNA degradation [10],[11]. Specifically, the hypothesis was that cellular enzymes known as uracil DNA glycosylases would recognise and remove uracil in the viral cDNA leaving abasic sites. These sites would then be cleaved by cellular apurinic/apyrimidinic endonucleases resulting in the degradation of single-stranded reverse transcripts. However, recent studies have challenged this theory. Several groups have now shown that knocking out or inhibiting the cellular uracil DNA glycosylases UNG2 and SMUG1 does not rescue the defect in viral cDNA accumulation [16],[17],[21]. Furthermore, there is mounting evidence to suggest that hypermutation can be dispensable for APOBEC-mediated antiviral activity (reviewed in [3]). For example, various APOBEC proteins are able to inhibit MMTV, HBV, AAV or retrotransposons with little or no discernible editing activity [22]-[24]; A3G expressed in unstimulated CD4+ T-cells can inhibit incoming HIV-1 without inducing widespread hypermutation [25]; levels of mutations detected in HIV-1 do not correlate with the degree of viral inhibition or cDNA levels [13],[21]; and finally, engineered catalytically inactive APOBEC mutants can still inhibit HIV-1, MMTV, HBV or retrotransposons in cultured cell experiments [14],[23],[24],[26],[27]. In the absence of editing, therefore, what would be the trigger for viral cDNA degradation?
###end p 9
###begin p 10
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Iwatani2">[28]</xref>
###xml 115 119 115 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Chelico1">[30]</xref>
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Mangeat1">[11]</xref>
###xml 500 504 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Bishop1">[13]</xref>
###xml 505 509 505 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Luo1">[20]</xref>
###xml 510 514 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Guo2">[31]</xref>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Li1">[32]</xref>
###xml 879 883 879 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Nguyen1">[33]</xref>
###xml 884 888 884 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Rosler1">[34]</xref>
###xml 333 338 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 657 662 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 746 749 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 842 845 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Alternatively, it is plausible that APOBEC proteins, which are known to bind both RNA and single stranded DNA [28]-[30], may be able to prevent the synthesis of cDNA by interfering with the process of reverse transcription. In this regard, various conflicting reports have suggested that A3G is able to inhibit numerous steps during HIV-1 replication, including primer tRNA annealing, minus and plus strand transfer, primer tRNA processing and removal, DNA elongation, and proviral integration [11], [13]-[20],[31],[32]. It is possible that minor blocks at any (or all) of these steps could, together, accumulate to produce the potent overall inhibition of HIV-1 infectivity. In addition, it has recently been reported that the observed block to HBV replication is not due to A3G-mediated DNA degradation, but instead due to an inhibition of HBV early minus strand DNA synthesis [33],[34].
###end p 10
###begin p 11
###xml 272 276 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Bishop1">[13]</xref>
###xml 277 281 277 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Holmes2">[14]</xref>
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Bishop2">[35]</xref>
###xml 756 760 756 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 985 989 985 989 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 256 261 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1194 1199 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We have previously shown that A3G and A3F can elicit a pronounced block to early viral DNA accumulation and that this decrease correlates well with the block to viral infectivity although these proteins induce very different levels of hypermutation during HIV-1 infection [13],[14],[35]. We therefore decided to employ an alternative methodology to examine the effects of APOBEC proteins on the early steps of reverse transcription more closely, namely using using viral particles isolated from cell supernatants to study natural endogenous reverse transcription (nERT). We show here that A3G-mediated inhibition of cDNA accumulation is independent of both the target cell and hypermutation. Using this assay system, we also show there is no defect in tRNAlys3 priming of reverse transcription in virions. However, a small decrease in the amount of cDNA can already be observed 16 bases after the start of reverse transcription, and this reduction amplifies with distance from the tRNAlys3 primer. The block to cDNA titrates with A3G concentration and can be induced by endogenous levels of A3G. Together with existing data, our results support the proposal that A3G inhibits the elongation of HIV-1 DNA by reverse transcriptase, probably by steric hindrance, rather than promoting the degradation of viral cDNA.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Inhibition of cDNA Accumulation Is Independent of Target Cell Type
###end title 13
###begin p 14
###xml 164 168 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Bishop1">[13]</xref>
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Holmes2">[14]</xref>
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Harris1">[10]</xref>
###xml 279 283 279 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Mangeat1">[11]</xref>
###xml 395 398 395 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 415 418 411 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 857 860 849 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 873 876 865 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Sheehy1">[1]</xref>
###xml 877 881 869 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Bishop2">[35]</xref>
###xml 882 886 874 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Thielen1">[36]</xref>
###xml 1272 1280 1264 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g001">Figure 1</xref>
###xml 1511 1519 1503 1511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g001">Figure 1</xref>
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 117 122 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 420 425 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 520 525 <span type="species:ncbi:9606">human</span>
###xml 846 851 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 939 944 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1064 1069 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We have previously shown that human A3G and A3F inhibit the accumulation of early (strong stop) cDNA products during HIV-1 infection of SupT1 cells (a T-cell line) [13],[14]. It has been proposed that this is due to specific degradation of viral cDNA by target cell enzymes [10],[11]. We therefore wanted to test the effects of A3G on cDNA accumulation in different target cells. We synthesized vif-deficient (Deltavif) HIV-1 in the presence or absence of A3G in 293T cells and used this virus to infect three different human T-cell lines or peripheral blood mononuclear cells (PBMCs). In case the expression of endogenous A3G affected the accumulation of viral cDNA, we chose two so-called permissive T-cell lines that express little or no endogenous A3G, SupT1 and CEM-SS, and one cell line, CEM, known to express A3G and be non-permissive for HIV-1/Deltavif replication [1],[35],[36]. PBMCs include CD4+ T-cells, the natural targets of HIV-1 infection, which also express A3G. Cells were harvested at different times after infection and the relative amounts of HIV-1 strong stop cDNA were measured by quantitative (q)PCR. As seen previously, in the absence of A3G, the level of reverse transcription products increased with time to a peak around 8 h and then declined (Figure 1, filled lines). The levels of transcripts detected in cells infected with virus produced in the presence of A3G were very low at all time points and only just detectable, regardless of which target cell culture had been infected (Figure 1, dotted lines). At the peak of accumulation, the amount of cDNA from these viruses ranged from approximately2-10% of the level of cDNA from control viruses made in the absence of A3G. There was no significant difference between PBMCs and T-cell lines, or between permissive and non-permissive cell types, indicating the inhibition of cDNA accumulation under these experimental conditions is independent of endogenous A3G in the target cell, and can occur in a range of different T-cells.
###end p 14
###begin title 15
###xml 13 18 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A3G inhibits HIV-1 cDNA accumulation regardless of target cell type.
###end title 15
###begin p 16
###xml 33 36 29 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 92 97 <span type="species:ncbi:9606">human</span>
Equivalent amounts of HIV-1/Deltavif produced from 293T cells in the presence or absence of human A3G were used to infect SupT1, CEM-SS, CEM, or PBMC target cells. Total DNA was harvested at the indicated times after infection, and the relative amounts of early reverse transcription products (strong stop) were measured using quantitative PCR analysis. Levels of cDNA are shown as percentages of the peak accumulation detected in the control (no APOBEC) reaction. Representative data from at least two independent experiments with each cell type are shown.
###end p 16
###begin title 17
Target Cell Proteins Are Dispensable for the Block to cDNA Accumulation
###end title 17
###begin p 18
###xml 388 392 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Kaiser1">[16]</xref>
###xml 393 397 393 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Mbisa1">[17]</xref>
###xml 398 402 398 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Langlois1">[21]</xref>
###xml 555 563 555 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 563 567 563 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Boone1">[37]</xref>
###xml 568 572 568 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Zhang2">[38]</xref>
###xml 781 785 781 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 878 881 874 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 1068 1077 1064 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2A</xref>
###xml 1429 1438 1421 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2A</xref>
###xml 1548 1557 1528 1537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2A</xref>
###xml 1720 1728 1696 1704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g001">Figure 1</xref>
###xml 1988 1997 1961 1970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2B</xref>
###xml 867 872 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2044 2049 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2147 2152 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
As the A3G-mediated inhibition of viral cDNA accumulation seemed to be independent of the type of target cell infected, we wondered whether any target cell factors were required for this effect at all. Previous studies have tested the contribution of particular cellular proteins to the antiviral activity of A3G by knocking down individual proteins, specifically uracil DNA glycosylases [16],[17],[21]. By employing a nERT assay where cell-free viral particles are incubated in the presence of dNTPs and a membrane pore-forming substance called melittin in vitro[37],[38], we could test the involvement of all target cell proteins on A3G's influence on viral cDNA accumulation at once. Under these conditions, reverse transcription of the viral RNA proceeds using the natural tRNAlys3 primer and virion reverse transcriptase enzyme. We carried out nERT reactions on HIV-1/Deltavif produced in 293T cells in the presence of increasing concentrations of A3G, and measured the amount of strong stop cDNA present at various times after the start of the reaction by qPCR (Figure 2A). As seen with infections of target cells, the amount of viral cDNA increased with time in all reactions, peaking around 3 h after the addition of nucleotides. Strikingly, the amount of strong stop DNA that accumulated decreased with increasing A3G concentration. Virions made in the presence of the highest dose of A3G (1 microg transfected plasmid; Figure 2A, purple line) only accumulated approximately5% of the amount detected in virions made in the absence of A3G (Figure 2A, red line). This was very similar to the decreases in strong stop cDNA seen in T-cell cultures when viruses were made in the presence of 1 microg of A3G plasmid (Figure 1), suggesting that additional factors present in target cells are not required for this defect. The decrease in cDNA accumulation also notably correlated with decreasing viral infectivity as measured in a single cycle infection of TZM beta-gal reporter cells (Figure 2B). Similar results were also obtained using an HIV-1 vector system (data not shown), confirming that this phenotype is not specific for the strain of HIV-1 used. Accordingly, because target cell proteins are dispensable for the A3G-mediated suppression of reverse transcript accumulation, we considered the nERT assay to be a simpler, more defined system with which to study this aspect of APOBEC protein function.
###end p 18
###begin title 19
###xml 13 18 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A3G inhibits HIV-1 cDNA accumulation in the absence of target cells and hypermutation.
###end title 19
###begin p 20
###xml 15 18 11 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 474 482 462 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g001">Figure 1</xref>
###xml 795 798 773 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 4 9 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 784 789 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) HIV-1/Deltavif viruses were generated from 293T transfected with a fixed amount of proviral plasmid (3 microg) and increasing amounts of A3G plasmid (from 0 to 1 microg). Viruses were subjected to natural endogenous reverse transcription reactions, and DNA was harvested at the indicated times after the addition of dNTPs. The relative amounts of early reverse transcription products (strong stop) were measured using quantitative PCR analysis and are represented as in Figure 1. (B) The virus preparations described in (A) were used in parallel to challenge TZM beta-gal indicator cells, and productive infection was measured after 24 h as the induction of beta-galactosidase activity, monitored using a chemiluminescent substrate. Infectivity is reported as counts per sec. (C) HIV-1/Deltavif viruses were produced from 293T cells in the presence of either control vector, wild-type (WT) A3G, WT A3F, or A3G/A3F variants with the catalytic glutamic acid residue altered to a glutamine. Viruses were subjected to natural endogenous reverse transcription reactions, and DNA was harvested at the indicated times after the addition of dNTPs. The relative amounts of early reverse transcription products (strong stop) were measured using quantitative PCR analysis. (D) The virus preparations described in (C) were used in parallel to challenge TZM beta-gal indicator cells, and viral infectivity was measured as in (B). All experiments were performed with at least two independent sets of viruses, representative results are shown.
###end p 20
###begin title 21
Hypermutation Is Dispensable for the Block to cDNA Accumulation
###end title 21
###begin p 22
###xml 151 154 147 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 329 333 325 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Holmes2">[14]</xref>
###xml 492 501 488 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2C</xref>
###xml 635 639 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Holmes2">[14]</xref>
###xml 781 790 765 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2C</xref>
###xml 929 938 913 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2C</xref>
###xml 1008 1017 992 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2B</xref>
###xml 1134 1143 1118 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2D</xref>
###xml 1715 1719 1695 1699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Bishop1">[13]</xref>
###xml 1720 1724 1700 1704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Holmes2">[14]</xref>
###xml 140 145 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1780 1785 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To confirm that catalytically inactive APOBEC mutant proteins could also function independently of any target cell proteins, we synthesized HIV-1/Deltavif in 293T cells in the presence of either control vector, wild-type (WT) A3G, WT A3F, or A3G/A3F variants with the catalytic glutamic acid residue substituted with a glutamine [14]. These viruses were then subjected to nERT followed by qPCR to detect strong stop cDNA. As above, reverse transcripts accumulated with time to a peak at 3 h (Figure 2C). Again, the levels of cDNA were reduced in viruses made in the presence of APOBEC proteins. Mirroring our previous results in cells [14], the catalytic A3G mutant E259Q inhibited cDNA accumulation to a lesser extent, than WT A3G; to approximately40% of control compared to <1% (Figure 2C, compare purple line with orange line). However, the catalytic A3F mutant E251Q had a very similar effect on cDNA accumulation to WT A3F (Figure 2C, compare green line with blue line). As seen with the A3G titration (Figure 2B), the degree of inhibition of cDNA accumulation closely reflected the inhibition of viral infectivity in TZM cells (Figure 2D). Considering panels A and B against panels C and D, it is remarkable that conditions that impart very similar comparative decreases in cDNA levels also reduce infectivity to similar extents: this point is illustrated by comparing the effects of 0.3 microg A3G (blue in the top panels, 90% reduction in nERT, 99% decrease in infectivity) with WT A3F (blue in the bottom panels, 91% reduction in nERT, 99% decrease in infectivity). These findings are entirely consistent with our previous observations correlating loss of viral infection with diminished cDNA accumulation [13],[14], and indicate that APOBEC proteins are able to inhibit HIV-1 cDNA accumulation without requiring hypermutation or any target cell factors.
###end p 22
###begin title 23
Endogenous A3G Has the Same Effect on Early cDNA Accumulation as A3G Expressed in 293T Cells
###end title 23
###begin p 24
###xml 278 282 278 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Xu1">[39]</xref>
###xml 406 422 406 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2A and 2B</xref>
###xml 861 864 857 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 1085 1089 1081 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Thielen1">[36]</xref>
###xml 1091 1100 1087 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g003">Figure 3A</xref>
###xml 1340 1349 1336 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g003">Figure 3B</xref>
###xml 1490 1499 1482 1491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g003">Figure 3A</xref>
###xml 1867 1870 1859 1862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Sheehy2">[5]</xref>
###xml 1871 1874 1863 1866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Mariani1">[7]</xref>
###xml 1875 1878 1867 1870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Yu1">[9]</xref>
###xml 1945 1954 1937 1946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g003">Figure 3B</xref>
###xml 2052 2055 2040 2043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 2178 2187 2162 2171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g003">Figure 3B</xref>
###xml 2284 2287 2264 2267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 2431 2435 2411 2415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Xu1">[39]</xref>
###xml 850 855 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1067 1072 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1602 1607 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1883 1888 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2041 2046 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2273 2278 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Most studies on A3G use exogenous expression systems which lend themselves to a wide variety of manipulations and can be appropriately controlled. However, it is likely that A3G is frequently expressed to higher levels in these systems than the endogenous protein is in T-cells [39]. As both the accumulation of reverse transcripts and viral infectivity decrease with increasing A3G plasmid concentration (Figure 2A and 2B), we wanted to compare the levels of A3G protein packaged into virions in these experiments with the level of endogenous A3G that is packaged. Unfortunately, we were unable to examine A3G incorporation in virions from H9 or Hut78 T-cell lines, as these cells release pelletable A3G into the medium that, in the context of infected cultures, co-purifies with viral particles (data not shown). For this reason, we passaged WT or HIV-1/Deltavif through another non-permissive T-cell line, CEM. While these cells do not constitutively secrete A3G, they express approximately 10-fold less A3G mRNA than H9, Hut78 or PBMCs, yet still block spreading HIV-1 replication [36]. Figure 3A shows that transfecting increasing amounts of A3G plasmid into 293T cells leads to comparative increases in A3G protein expression (lanes 4-8). This also leads to corresponding increases in the amount of A3G packaged into viral particles (Figure 3B, lanes 4-8). The amount of A3G expressed in CEM cells is equivalent to 293T cells transfected with between 0.03 and 0.1 microg A3G plasmid (Figure 3A, compare lane 1 with lanes 5 and 6). The level, as expected, is reduced in CEM cells infected with WT HIV-1 (lane 2) due to Vif expression inducing the degradation of A3G. Expression is not completely abolished as a proportion of these cells are presumably not infected at the time of sampling and therefore still express normal levels of A3G. As previously reported [5],[7],[9], WT HIV-1 particles from CEM cells do not package detectable A3G (Figure 3B, lane 2). As with the cellular expression, the amount of endogenous A3G packaged into HIV-1/Deltavif virions corresponds to that detected in viruses from 293T cells transfected with between 0.03 and 0.1 microg A3G plasmid (Figure 3B, compare lane 3 with lanes 5 and 6). This compares well with a previous report where HIV-1/Deltavif virions from PBMCs packaged the equivalent amount of A3G as viruses made in 293T cells transfected with a 1:5 molar ratio of A3G: proviral DNA [39]. In our experiment, transfecting 0.3 microg A3G plasmid also gives approximately a 1:5 molar ratio, and CEM cells express approximately10-fold less A3G than PBMCs, corresponding to 0.03 microg A3G plasmid.
###end p 24
###begin title 25
Endogenous A3G has the same effect on early cDNA accumulation as equivalent amounts of A3G expressed in 293T cells.
###end title 25
###begin p 26
###xml 121 125 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif,</italic>
###xml 186 189 178 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 608 611 588 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 101 106 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 110 115 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 175 180 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 567 572 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 588 593 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 597 602 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) Immunoblot analysis of A3G expression in uninfected CEM cells, CEM cells infected with either WT HIV-1 or HIV-1/Deltavif, or 293T cells transfected with a fixed amount of HIV-1/Deltavif proviral plasmid (3 microg) and increasing amounts of A3G plasmid (0, 0.03, 0.1, 0.3 or 1 microg). Below the blot, the graph shows the quantity of A3G expressed relative to HSP90. (B) Viral incorporation of A3G was measured by immunoblot analysis of purified virions harvested from the cells in (A). Below the blot, the graph shows the quantity of A3G incorporated relative to HIV-1 CA-p24. (C) WT HIV-1 or HIV-1/Deltavif were passaged through CEM cells and used in natural endogenous reverse transcription reactions. DNA was harvested at the indicated times after the addition of dNTPs, and the relative amounts of early reverse transcription products (strong stop) were measured using quantitative PCR analysis. (D) The virus preparations from CEM cells described in (C) were used in parallel to challenge TZM beta-gal indicator cells, and productive infection was measured as the induction of beta-galactosidase activity, monitored using a chemiluminescent substrate. Infectivity is reported as counts per sec.
###end p 26
###begin p 27
###xml 160 163 156 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 291 300 283 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g003">Figure 3C</xref>
###xml 306 315 298 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2A</xref>
###xml 424 428 416 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Ohagen1">[40]</xref>
###xml 149 154 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
When a nERT reaction was carried out on viruses from CEM cells, followed by qPCR for strong stop cDNA, the relative amount of viral cDNA detected in HIV-1/Deltavif virions also corresponded to that in viruses from 293T cells transfected with between 0.03 and 0.1 microg A3G plasmid (compare Figure 3C with Figure 2A). The reduction in cDNA levels is similar to that detected previously in CEM cells by non-PCR based methods [40]. This implies that endogenous A3G has a similar effect on cDNA accumulation as exogenously expressed A3G in 293T cells. In other words, the specific activity of the protein with respect to this attribute is similar irrespective of the cell type used for expression.
###end p 27
###begin p 28
###xml 38 47 38 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2B</xref>
###xml 106 109 102 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 239 242 219 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 379 388 347 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g003">Figure 3D</xref>
###xml 560 564 528 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Han1">[41]</xref>
###xml 613 617 581 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Shirakawa1">[42]</xref>
###xml 618 622 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Watashi1">[43]</xref>
###xml 865 869 833 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Thielen1">[36]</xref>
###xml 372 377 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Based on the 293T titration data from Figure 2B, this modest reduction in strong stop cDNA levels in Deltavif viruses from CEM cells would be expected to lead to between an approximately55-90% reduction in viral infectivity. However, Deltavif viruses from CEM cells were slightly less infectious than this, showing approximately95% reduction in infectivity compared to WT HIV-1 (Figure 3D). This suggests that the antiviral properties of A3G may be accentuated when expressed in T-cells either through the action of cofactors provided by virus producing cells [41] or through direct effects on the protein itself [42],[43]. Regarding the former possibility, a recent report showing that endogenous A3G has significantly lower cytidine deaminase activity than A3G produced in 293T cells would indicate that any additional activities are independent of hypermutation [36].
###end p 28
###begin title 29
A3G Does Not Affect Initiation of Reverse Transcription
###end title 29
###begin p 30
###xml 487 491 487 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 105 110 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Several possible mechanisms could be responsible for the APOBEC-mediated decrease in the accumulation of HIV-1 strong stop cDNA. Whilst rapid degradation is still a formal possibility, we have shown that it would have to occur in the absence of hypermutation and be driven entirely by components packaged into the virion from the producer cell. The alternative explanation posits that A3G inhibits the synthesis of cDNA. This could be achieved by A3G inhibiting the annealing of the tRNAlys3 primer to the primer binding site, preventing reverse transcriptase from recognising the primer and initiating reverse transcription, inducing a specific block (i.e., at a particular site) after initiation of reverse transcription but before the completion of strong stop, or by imparting a general decrease in the processivity of reverse transcriptase itself. To begin to distinguish between these possibilities, we decided to look at the initiation of reverse transcription by setting up a novel assay system.
###end p 30
###begin p 31
###xml 22 25 18 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 262 266 258 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 286 290 282 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 429 433 425 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 838 842 834 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 869 878 865 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g004">Figure 4A</xref>
###xml 904 908 900 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 1085 1089 1081 1085 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 1310 1314 1306 1310 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 1328 1332 1324 1328 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 1369 1378 1365 1374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g004">Figure 4A</xref>
###xml 1436 1440 1432 1436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 1559 1568 1555 1564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g004">Figure 4B</xref>
###xml 1775 1779 1771 1775 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 11 16 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
As before, HIV-1/Deltavif viruses were made in 293T cells in the presence or absence of A3G and nERT reactions were performed. In these reactions, however, the mix of dNTPs was replaced with just biotinylated dCTP: cytidine being the first base added to the tRNAlys3 primer. If the tRNAlys3 primer was correctly bound to the genomic RNA, and reverse transcription could be initiated, the addition of dCTP would result in the tRNAlys3 primer becoming biotinylated. Total RNA from each time point was purified and an aliquot was incubated in streptavidin-coated qPCR plates. This allowed biotinylated dCMP-tRNA to bind specifically to the plate. A set of qPCR standards and an aliquot of total purified RNA for each sample was then added to the plate as controls, and a one-step quantitative reverse-transcriptase PCR was performed for tRNAlys3. The results are shown in Figure 4A. The amount of total tRNAlys3 was constant for all samples (data not shown), indicating each sample had received equal input virus and all RNA purification steps were similarly efficient. The amount of tRNAlys3 in the bound samples however, increased with time from trace amounts in the control samples to substantial levels at 30 min, continuing to increase slightly to 2 h (data not shown). The ratio of biotinylated (bound) tRNAlys3 to total tRNAlys3 therefore also increased with time (Figure 4A), implying biotin was being efficiently added to the tRNAlys3 primer during the nERT reaction. Importantly, although the presence of A3G significantly decreased viral infectivity (Figure 4B), we were unable to detect any difference in the amount of tRNA biotinylation between viruses made in the presence or absence of A3G. This suggests that A3G does not inhibit either the placement of the tRNAlys3 primer or the initiation of reverse transcription from that primer.
###end p 31
###begin title 32
A3G does not affect initiation of reverse transcription.
###end title 32
###begin p 33
###xml 37 40 33 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 450 454 446 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 539 543 535 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 603 607 599 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 621 625 617 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 26 31 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 96 101 <span type="species:ncbi:9606">human</span>
(A) Equivalent amounts of HIV-1/Deltavif produced from 293T cells in the presence or absence of human A3G were incubated with biotinylated-dCTP during modified natural endogenous reverse transcription reactions. Samples were taken at 2, 30, or 120 min after the addition of biotinylated-dCTP, and at 120 min for the control reaction with no dNTPs. Reverse transcription initiation was assessed by measuring both the amount of biotinylated primer tRNAlys3 that bound to a streptavidin-coated 384-well qPCR plate and the total amount of tRNAlys3 purified from each reaction. The ratio of biotinylated tRNAlys3 to total tRNAlys3 is plotted on the y-axis. Error bars show the standard deviation of four independent viral preparations. (B) The same virus preparations described in (A) were used in parallel to challenge TZM beta-gal indicator cells, and productive infection was measured as the induction of beta-galactosidase activity, monitored using a chemiluminescent substrate. Infectivity is reported as counts per sec.
###end p 33
###begin title 34
The Decrease in cDNA Levels Is Greater with Increasing Elongation
###end title 34
###begin p 35
###xml 367 369 367 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 867 876 867 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g005">Figure 5A</xref>
###xml 1060 1069 1060 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g005">Figure 5A</xref>
As the initiation of reverse transcription is normal in the presence of A3G, it is possible that A3G inhibits the ensuing elongation of reverse transcripts, either continuously or at a specific point(s) during early cDNA synthesis. Initially, we attempted to visualise early reverse transcription products on polyacrylamide gels after performing nERT reactions using 32P-labelled dNTPs. However, this was not sensitive enough to detect small cDNA fragments, other than strong stop DNA, even in the absence of A3G (data not shown). Therefore, to investigate the effect on cDNA elongation, we designed qPCR primers and probes for monitoring different regions within the strong stop cDNA fragment. For the purpose of this analysis, we assumed that if a product amplified, then the template sequence must reach the 5' end of the reverse primer for each primer/probe set (Figure 5A). The length of the reverse transcript was therefore taken as the number of bases from the 3' end of the anti-primer binding site (anti-PBS) to the 5' end of the reverse qPCR primer (Figure 5A). Our standard strong stop primers amplify a region from R into U5, implying any reverse transcripts detected with this primer/probe set are at least 137 bases long. Our new primer/probe sets amplified reverse transcripts of 16 or 36 bases. As these primer/probe sets amplified templates that were part RNA, part DNA, a reverse transcription step was carried out before qPCR to ensure efficient amplification by DNA polymerase.
###end p 35
###begin title 36
A3G inhibits the accumulation of longer reverse transcription products more than shorter ones.
###end title 36
###begin p 37
###xml 260 263 256 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 552 560 548 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g004">Figure 4</xref>
###xml 249 254 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) Schematic to show how the length of the reverse transcript was measured for each primer/probe set. The exact positions of the primers and probe are not depicted. (B) Natural endogenous reverse transcription reactions were performed for 2 h with HIV-1/Deltavif produced in the presence or absence of A3G. Quantitative PCR was carried out with different primer/probe sets to measure the amount of viral cDNA of the various lengths indicated. The amount of cDNA in virions with A3G is plotted as a percentage of that in virions without A3G. Data from Figure 4 are included to show the relative amount of reverse transcripts of 1 base in length. Each point represents an independent pair of viral preparations. Lines indicate the mean value.
###end p 37
###begin p 38
###xml 496 505 496 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g005">Figure 5B</xref>
###xml 812 816 812 816 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
Viruses were synthesized with or without A3G as before and nERT reactions were performed. Samples were taken after 2 h, added to cells-to-signal lysis buffer and an aliquot of the lysate was taken directly to a one-step quantitative reverse-transcriptase PCR. The amount of each cDNA detected in virions in the presence of A3G was calculated as a percentage of that detected in the absence of A3G. This was plotted against the length of the reverse transcript amplified by each primer/probe set (Figure 5B). Data from independent preparations of pairs of viruses are plotted as individual points to illustrate the experimental variation and the mean for each primer/probe set is shown by a line. It is clear that the amount of cDNA detected in the presence of A3G decreased with increasing distance from the tRNAlys3 primer. There was only an approximately20% decrease in the amount of cDNA reaching 16 bases, increasing to an approximately35% decrease in the amount of cDNA reaching 36 bases, and an approximately85% decrease in cDNA 137 bases long. Thus, A3G appears to inhibit the elongation of reverse transcripts.
###end p 38
###begin p 39
Importantly, these effects on cDNA synthesis under nERT conditions are specific for the viral RNA template rather than directly inhibiting reverse transcriptase itself as reactions performed using viral lysates, exogenous poly-rA template and oligo-dT primer were unaffected by the presence of A3G in virions (data not shown).
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
###xml 246 249 246 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Courcoul1">[44]</xref>
###xml 318 322 318 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-vonSchwedler1">[47]</xref>
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Mangeat1">[11]</xref>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Bishop1">[13]</xref>
###xml 410 414 410 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Luo1">[20]</xref>
###xml 415 419 415 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Guo2">[31]</xref>
###xml 899 902 899 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Holmes1">[3]</xref>
###xml 1027 1031 1027 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Kaiser1">[16]</xref>
###xml 1032 1036 1032 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Mbisa1">[17]</xref>
###xml 1037 1041 1037 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Langlois1">[21]</xref>
###xml 1157 1161 1157 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Holmes2">[14]</xref>
###xml 1466 1470 1466 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Holmes2">[14]</xref>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 260 265 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Members of the APOBEC family of cytidine deaminases inhibit HIV-1 infection. However, there are still many uncertainties and controversies as to exactly how they exert their anti-viral effects. Before the identification of A3G, it was known that vif-deficient HIV-1 produced less provirus in non-permissive cells [44]-[47], and this has been confirmed in recent studies using A3G expression vectors [11], [13]-[20],[31]. There are two ways this defect could occur; either reverse transcripts could be synthesized but then degraded before they can form integrated provirus, or there could be a block to DNA synthesis. The former mechanism was initially favoured by many since the APOBEC mediated appearance of uracils in DNA could serve as the signal for recognition by cellular DNA repair enzymes and nucleases. However, anti-viral activity is not always associated with hypermutation, (reviewed in [3]), and the enzymes responsible for recognising and removing uracils in DNA are apparently expendable for anti-viral function [16],[17],[21]. Moreover, deaminase defective variants of APOBEC proteins are still able to reduce the accumulation of viral cDNA [14], suggesting that antiviral effects can be achieved by a non-editing mechanism(s). While this effect was first noted with A3G, we have shown that it is more pronounced for A3F, as non-editing A3F mutants display antiviral phenotypes that closely match the wild-type protein over a range of concentrations [14]. Accordingly, since we have previously shown that the accumulation of reverse transcripts correlates well with viral infectivity, we set out to investigate this effect further.
###end p 41
###begin p 42
###xml 68 76 68 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g001">Figure 1</xref>
###xml 671 680 671 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2A</xref>
###xml 1062 1071 1062 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2C</xref>
Initially, we measured cDNA accumulation in different target cells (Figure 1). Similar results were seen in both permissive and non-permissive cell types, indicating that the presence of endogenous A3G in the target cell causes no additional inhibition, even in activated PBMCs. Moreover, this implied either that any target cell factors involved in diminishing cDNA accumulation are present in all cell types studied or that these effects do not require any target cell factors. To examine this, we established a natural endogenous reverse transcription (nERT) assay and found that the extent of inhibition was highly reminiscent of that seen in target cell infections (Figure 2A), revealing that no target cell factors are necessary for the block to cDNA accumulation. Whilst this does not refute a degradative mechanism for cDNA turnover, it does eliminate proteasomal degradation and implies that any endo- or exonucleases involved must be copurified or packaged into viral particles. As cDNA levels were also reduced by deaminase deficient APOBEC variants (Figure 2C), an alternative trigger for degradation other than uracils in DNA would be necessary. Theoretically, A3G could cause the specific packaging of an as yet unidentified nuclease responsible for degrading nascent reverse transcripts. However, there is no direct evidence in the literature for A3G-induced degradation and, as we expand upon below, this is not our preferred explanation.
###end p 42
###begin p 43
###xml 346 354 346 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g004">Figure 4</xref>
###xml 433 437 433 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 455 463 455 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 501 505 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Guo1">[19]</xref>
###xml 506 510 506 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Guo2">[31]</xref>
###xml 511 515 511 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Yang1">[48]</xref>
###xml 688 696 688 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 723 727 723 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Iwatani1">[15]</xref>
###xml 933 937 933 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 171 176 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The fact that the block to cDNA accumulation can be detected in nERT reactions allowed us to investigate this process in ways that are not possible in cells, but resemble HIV-1 infections more closely than reconstitution studies using purified components. For instance, we were able to monitor the initiation of reverse transcription in virions (Figure 4). Recently, the Kleiman group have reported that both A3G and A3F prevent tRNAlys3 primer annealing in vitro via an interaction with nucleocapsid [19],[31],[48]. However, annealing was not measured directly, and in a very thorough recent study, Iwatani et al., found no effect on primer placement or initiation of the +1 cDNA, again in vitro using purified components [15]. By using a novel variation of the nERT assay to study reverse transcription initiation in viral particles, we have shown that A3G does not affect the addition of a biotinylated dCTP first base to the tRNAlys3 primer. We acknowledge that some reverse transcription may have initiated prior to incubation with biotinylated dCTP, but as we detect more than a two log increase in biotinylation after 30 min, we assert that this represents significant initiation in our experiment.
###end p 43
###begin p 44
###xml 155 163 155 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g001">Figure 1</xref>
###xml 185 194 185 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figures 2</xref>
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g005">5</xref>
###xml 702 706 702 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 715 724 715 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g005">Figure 5B</xref>
Although there was no block to the initiation of reverse transcription, we could detect a significant reduction in the level of strong stop cDNA in cells (Figure 1) and nERT reactions (Figures 2 and 5) in the presence of A3G. This indicates either that there is an early block to reverse transcription or that cDNA is degraded very rapidly. To address whether reverse transcription was inhibited at a particular position or whether elongation was progressively impeded, we designed new qPCR primer/probe sets to measure reverse transcripts shorter than the 137 nucleotide standard strong stop product. The amounts of cDNA detected in the presence of A3G decreased with increasing distance from the tRNAlys3 primer (Figure 5B), from an approximately20% reduction in cDNA reaching 16 bases to an approximately35% decrease at 36 bases and an approximately85% decrease at 137 bases. Some variation was seen between independent virus preparations (indicated by individual points) most likely reflecting minor differences in A3G expression and packaging. From these data, it therefore appears that there is no single abrupt point of termination to reverse transcription.
###end p 44
###begin p 45
###xml 214 222 214 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Iwatani1">[15]</xref>
###xml 528 536 528 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g005">Figure 5</xref>
###xml 670 673 670 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Bogerd1">[6]</xref>
###xml 675 679 675 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Iwatani2">[28]</xref>
###xml 681 685 681 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-GalloisMontbrun1">[49]</xref>
###xml 686 690 686 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Wang1">[52]</xref>
###xml 856 860 856 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Nguyen1">[33]</xref>
###xml 186 191 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 265 270 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 700 703 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
The results of our study are in complete agreement with a recent report from Iwatani et al. who show that purified recombinant A3G is able to inhibit the elongation of exogenous cDNA by HIV-1 reverse transcriptase in vitro[15]. They hypothesise that A3G binding to HIV-1 RNA or single stranded DNA physically blocks RT movement along the template. If A3G bound genomic RNA at random points, this would imply that the likelihood of synthesizing a given product would decrease with increasing product length, as borne out here in Figure 5. The fact that A3G has been shown to bind several different RNA molecules implies that binding is not particularly sequence specific [6], [28], [49]-[52]. Work on HBV has recently revealed that A3G is also able to inhibit the early steps in minus-strand DNA synthesis in this virus via a block to DNA strand elongation [33].
###end p 45
###begin p 46
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Mbisa1">[17]</xref>
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Anderson1">[18]</xref>
###xml 170 174 170 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Luo1">[20]</xref>
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Holmes2">[14]</xref>
###xml 594 610 594 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2A and 2B</xref>
Other groups have reported a less dramatic decrease in early products than we see here, with escalating reductions at progressively later stages of replication [17],[18],[20]. Indeed, we have also published a greater decrease in the levels of later products compared to early transcripts [14]. The difference in the magnitude of the early effect between different groups has been attributed to differences in A3G expression levels, and we concur with this view since we show clearly that both the levels of early cDNA accumulation and infectivity titrate down with ascending A3G concentration (Figure 2A and 2B).
###end p 46
###begin p 47
###xml 182 191 182 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figures 2</xref>
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g003">3</xref>
Whilst the levels of endogenous A3G expression and viral incorporation were low in CEM cells, the effect on early cDNA accumulation was consistent with that seen with exogenous A3G (Figures 2 and 3). We note, however, that the relative deficit in infectivity imparted by APOBEC proteins in CEM cells is greater than anticipated on the bases of the nERT assay. Unfortunately, we found the efficiency of strand transfer and second strand synthesis to be very low in nERT reactions, and therefore it was not possible to use this system to investigate the effect on later steps in reverse transcription with any degree of quantification or certainty (data not shown). Possible underlying reasons are discussed above, and are a subject for future investigations. Importantly, a mode of action that involves direct binding of A3G to viral RNA would be expected to be sensitive to A3G concentration: if A3G can bind to multiple regions of the RNA genome with equal preference, then the probability of binding to a region within R or U5, and therefore blocking strong stop cDNA synthesis, would increase with A3G concentration. Theoretically, a single molecule of A3G may be all that would be required to inhibit the synthesis of a full length reverse transcript, such that even low levels of endogenous A3G would be sufficient to prevent viral infection.
###end p 47
###begin p 48
###xml 435 442 435 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 442 445 442 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Mariani1">[7]</xref>
###xml 447 451 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Harris1">[10]</xref>
###xml 452 456 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Zhang1">[12]</xref>
###xml 458 462 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Bishop2">[35]</xref>
###xml 464 468 464 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Lecossier1">[53]</xref>
###xml 469 473 469 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Vartanian1">[56]</xref>
###xml 612 616 612 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Thielen1">[36]</xref>
###xml 689 692 685 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 791 794 783 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 891 895 883 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Knoepfel1">[57]</xref>
###xml 948 955 940 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 678 683 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 780 785 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1048 1053 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Based on recent findings, we suggest that the relative contribution of editing and non-editing effects to the antiviral phenotype of A3G may depend upon its circumstances. If the inhibition of cDNA synthesis is inefficient, the resulting nascent transcripts may still be inactivated via hypermutation and loss of genetic integrity, and the production of such mutated viral sequences has been well documented in both cultured cells and in vivo[7], [10]-[12], [35], [53]-[56]. Interestingly, the editing capability of endogenous A3G in cultured T-cells appears to be reduced compared to A3G produced in 293T cells [36]. In addition, viral cDNAs recovered from PBMCs infected with HIV-1/Deltavif harbour lower levels of G-to-A mutations compared to cDNAs from H9 cells infected with HIV-1/Deltavif, both in terms of the number of clones carrying mutations and the number of mutations per clone [57]. This might suggest a lesser role for hypermutation in vivo, although this issue requires further investigation. Nevertheless, the capacity to suppress HIV-1 infection via dual mechanisms presumably serves to enhance the potency of this class of antiviral proteins.
###end p 48
###begin p 49
###xml 48 51 44 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 152 156 148 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Miyagi1">[58]</xref>
###xml 157 161 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Schumacher1">[59]</xref>
###xml 441 449 437 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2</xref>
###xml 454 458 450 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Holmes2">[14]</xref>
###xml 37 42 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recently, two groups have shown that HIV-1/Deltavif can replicate in stable cell lines expressing deaminase-defective A3G mutants but not wild-type A3G [58],[59]. They have interpreted these results as proving that deamination is essential for A3G activity. We suggest that such observations should be interpreted with caution as we have shown that the A3G E259Q mutant also has a substantially reduced ability to inhibit cDNA accumulation (Figure 2 and [14]). An alternative explanation for these findings is that disruption of the deaminase motif of A3G also affects an attribute necessary for inhibiting reverse transcription; since the C-terminal deaminase domain of A3G must engage nucleic acids for the purpose of editing, one possibility is that this defect could be in RNA binding. At present, it is unclear what effects such mutations have on the protein structure and function.
###end p 49
###begin p 50
###xml 176 180 176 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 347 351 347 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 585 590 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In this study, we have shown that A3G-mediated inhibition of cDNA accumulation occurs independent of both the target cell and hypermutation. Although there is no defect in tRNAlys3 priming of reverse transcription, a small decrease in the amount of cDNA can already be observed at 16 bases, and this reduction increases with distance from the tRNAlys3 primer. These data bolster the argument against a degradative mechanism being responsible for the decreases in viral cDNA that are observed in the presence of A3G, and support the proposal that A3G inhibits the elongation of nascent HIV-1 cDNA by steric hindrance of reverse transcriptase through direct binding to viral genomic RNA.
###end p 50
###begin title 51
Materials and Methods
###end title 51
###begin title 52
Plasmid Constructs
###end title 52
###begin p 53
###xml 91 94 91 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Sheehy1">[1]</xref>
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Newman1">[27]</xref>
###xml 133 137 133 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Holmes2">[14]</xref>
###xml 181 184 177 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 213 216 205 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 260 264 252 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Bishop2">[35]</xref>
###xml 81 86 <span type="species:ncbi:9606">human</span>
###xml 185 190 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
All APOBEC proteins were expressed from pcDNA3.1 as previously described; for WT human A3G [1], A3G E259Q [27], WT A3F and A3F E251Q [14]. Expression vectors for wild type and Deltavif HIV-1 (pIIIB and pIIIB/Deltavif, respectively), have been described before [35], and contain a mutation at nucleotide 567 of the provirus to create a G to A substitution in the U5 region of the 5'-LTR, that would copy to the 3'-LTR during reverse transcription.
###end p 53
###begin title 54
Cells and Virus Production
###end title 54
###begin p 55
###xml 63 66 59 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 274 282 270 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2</xref>
###xml 284 285 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g003">3</xref>
###xml 301 304 289 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 441 449 429 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000231-g002">Figure 2</xref>
###xml 815 818 783 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 1248 1250 1210 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA</sup>
###xml 67 72 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 819 824 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 861 887 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
All cell lines were maintained under standard conditions. Deltavif HIV-1 stocks were typically prepared by co-transfection of 293T cells with proviral plasmid and A3G expression plasmid (or empty pcDNA3.1 vector) at a ratio of 3:1. For the A3G titration experiment shown in Figure 2, 3 microg of Deltavif provirus was co-transfected with varying amounts of A3G plasmid as indicated. For the experiment that included A3F and A3G/A3F mutants (Figure 2) a ratio of 1:1 provirus to APOBEC expression vector was used. The media was changed approximately18 h after transfection and replaced with DMEM containing 20 microl/ml RQ1-DNase (Promega). After 8 h, the cells were washed and fresh media was added for a further 17 h, before virus containing supernatants were harvested. To study endogenous A3G, wild-type or Deltavif HIV-1 pseudotyped with the G-protein from vesicular stomatitis virus was made in 293T cells and used to infect CEM cells by spin infection at 1200xg for 2.5 h at 20degreesC. The cells were extensively washed and allowed to grow for 24 h before the media was changed again, and virus containing supernatants were harvested 16 h following this. All viral titres were quantitated by enzyme-linked immunosorbent assay (ELISA) for p24CA content.
###end p 55
###begin title 56
Viral Infections
###end title 56
###begin p 57
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 107 111 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000231-Wei1">[60]</xref>
###xml 150 152 147 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA</sup>
Viral infectivities were determined in single-cycle assays by challenging 105 TZM-beta-gal indicator cells [60] with viruses corresponding to 5 ng p24CA, and measuring the induced expression of beta-galactosidase activity in cell lysates after approximately28 h, using the Galacto-Star system from Applied Biosystems.
###end p 57
###begin p 58
###xml 97 99 97 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA</sup>
###xml 116 117 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 404 408 388 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dpn1</italic>
For quantitative PCR analysis of cDNA in target cells, viral preparations containing 30 ng of p24CA were added to 106 SupT1, CEM-SS or CEM cells or PBMCs rotating at 4degreesC for 2 h. Cells were then washed, resuspended in fresh RPMI media, and incubated at 37degreesC for 0-24 h. Total DNA was purified using the DNeasy kit from Qiagen, and eluted in a total volume of 200 microl. After treatment with Dpn1 for 2 h at 37degreesC, 2 microl of DNA was analysed by real-time quantitative PCR.
###end p 58
###begin title 59
Natural Endogenous Reverse Transcription Assays (nERT)
###end title 59
###begin p 60
###xml 45 47 45 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA</sup>
###xml 158 159 152 153 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 596 600 572 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dpn1</italic>
Viral preparations containing 10-25 ng of p24CA were pelleted by centrifugation for 1 h at 20,000xg at 4degreesC. Virions were resuspended in PBS, 2.5 mM MgCl2, 15 microg/ml melittin and 1 mM dNTPs, and incubated at 37degreesC. Control reactions were incubated without any dNTPs for the same length of time as the longest time point. At the specified time points, aliquots were removed and equal volumes of PBS containing 40 microg/ml "carrier" salmon sperm DNA added. DNA was then purified using using the DNeasy kit from Qiagen, and eluted in a total volume of 200 microl. After treatment with Dpn1 for 2 h at 37degreesC, 2 microl of DNA was analysed by real-time quantitative PCR. For later experiments, an equal volume of 2x Cells-to-signal lysis buffer (Ambion) was added instead of PBS with carrier DNA, and samples were diluted 1:10 in water before analysing 2 microl directly in real-time quantitative PCR.
###end p 60
###begin title 61
Reverse Transcription Initiation nERT Assay
###end title 61
###begin p 62
###xml 163 164 163 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1054 1058 1014 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
For this assay, a nERT reaction was performed essentially as above, with the exception of the dNTP addition: pelletted virions were resuspended in PBS, 2.5 mM MgCl2, 15 microg/ml melittin and 0.5mM biotin-11-dCTP (Jena Bioscience), and incubated at 37degreesC. Control reactions were incubated without any dNTPs for 2 h. At the specified time points, aliquots were removed, added to QIAzol lysis buffer (Qiagen) and frozen at -80degreesC. RNA was purified using the Qiagen miRNeasy kit and eluted in 30 microl of water. 2 microl 10x PBS was added to 18 microl RNA to make the final samples 1xPBS and the samples were heated at 95-100degreesC for 3 min and cooled instantly on ice to separate tRNA from genomic RNA. Samples were then added to streptavidin coated, 384-well, Strep Thermo-Fast plates (Abgene) and incubated at 37degreesC for 30 min. Plates were extensively washed and all liquid aspirated. Standards and aliquots of total purified RNA were added to the plates before the addition of Ag-path-ID One-Step RT-PCR Kit reagents (Ambion) and tRNAlys3 levels were measured by quantitative PCR analysis.
###end p 62
###begin title 63
Quantitative PCR
###end title 63
###begin p 64
###xml 151 173 151 173 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TAACTAGGGAACCCACTGC</named-content>
###xml 186 209 186 209 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCTAGAGATTTTCCACACTG</named-content>
###xml 229 265 229 265 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-FAM-ACACAACAGACGGGCACACACTA-TAMRA</named-content>
###xml 600 603 578 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 640 643 614 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 604 609 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Strong stop reverse transcription products were detected using primers that amplify the region between nucleotides 500 and 635 of the provirus: oHC64 (5'-TAACTAGGGAACCCACTGC) and oHC65 (5'-GCTAGAGATTTTCCACACTG) with probe oHC66 (5'-FAM-ACACAACAGACGGGCACACACTA-TAMRA). Reactions were performed in triplicate, in TaqMan Universal PCR master mix (UNG-less) using 900 nM of each primer, and 250 nM probe. After 10 min at 95degreesC, reactions were cycled through 15 sec at 95degreesC followed by 1 min at 60degreesC for 40 repeats, carried out on an ABI Prism model 7900HT (Applied Biosystems). The Deltavif-HIV-1 expression vector, pIIIB/Deltavif, was diluted into purified SupT1 cellular DNA to create a series of control samples that were used to calculate relative cDNA copy numbers and confirm the linearity of the assay.
###end p 64
###begin p 65
###xml 4 8 4 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 48 78 48 78 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTCGGTAGAGCATCAGACTTTTAATCT</named-content>
###xml 104 139 104 139 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCCCCCCGTGGCGCCCGAACAGGGACTTGAAC</named-content>
###xml 173 198 173 198 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-FAM-AGGGTCCAGGGTTC-MGB</named-content>
###xml 225 298 225 298 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCCCCCCGTGGCGCCCGAACAGGGACTTGAACCCTGGACCCTCAGATTAAAAGTCTGATGCTCTACCGAC</named-content>
###xml 427 431 427 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
tRNAlys3 was detected using primers tRNA-15for (5'-GTCGGTAGAGCATCAGACTTTTAATCT) and Long PBS-G-(C)7rev (5'-CCCCCCCGTGGCGCCCGAACAGGGACTTGAAC) with MGB probe Probe-tRNA43for (5'-FAM-AGGGTCCAGGGTTC-MGB). An oligo with sequence: 5'-CCCCCCCGTGGCGCCCGAACAGGGACTTGAACCCTGGACCCTCAGATTAAAAGTCTGATGCTCTACCGAC was serially diluted in water to create a standard curve. Note that this primer/probe set was originally designed to detect tRNAlys3 with a 3' extension. One-step quantitative reverse transcription PCR was performed using the Ag-path-ID One-Step RT-PCR Kit from Ambion using 20 microl reaction volumes and final primer and probe concentrations of 450 nM and 125 nM respectively. Cycling conditions were 45degreesC for 15 min then 95degreesC for 10 min, followed by 40 cycles of 15 sec at 95degreesC and 45 sec at 60degreesC.
###end p 65
###begin p 66
###xml 91 95 91 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
###xml 225 249 225 249 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGAAAATCTCTAGCAGTGGCG</named-content>
###xml 323 346 323 346 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TGAGGGTCCAGGGTTCAAGT</named-content>
###xml 362 389 362 389 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CAGACCCTTTTAGTCAGTGTGGAA</named-content>
###xml 418 450 418 450 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-FAM-CCTGTTCGGGCGCCACTGCT-BHQ1</named-content>
###xml 477 588 477 588 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;GTCGGTAGAGCATCAGACTTTTAATCTGAGGGTCCAGGGTTCAAGTCCCTGTTCGGGCGCCACTGCTAGAGATTTTCCACACTGACTAAAAGGGTCTGAGGGATCTCTA</named-content>
###xml 901 905 897 901 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lys3</sup>
Earlier products of reverse transcription either 16 or 36 bases from the 3' end of the tRNAlys3 primer were detected with set 2 or set 3 primer/probe sets respectively. Set 2 primer sequences were: tRNA-15for and PBSU5-rev, (5'-GGAAAATCTCTAGCAGTGGCG) with MGB probe Probe-tRNA43for. Set 3 primer sequences were tRNA-41for (5'-TGAGGGTCCAGGGTTCAAGT) and U5-rev-3 (5'-CAGACCCTTTTAGTCAGTGTGGAA) with probe Probe-PBSU5f-3 (5'-FAM-CCTGTTCGGGCGCCACTGCT-BHQ1). An oligo with sequence: 5'GTCGGTAGAGCATCAGACTTTTAATCTGAGGGTCCAGGGTTCAAGTCCCTGTTCGGGCGCCACTGCTAGAGATTTTCCACACTGACTAAAAGGGTCTGAGGGATCTCTA was serially diluted in water to create a standard curve. One-step quantitative reverse transcription PCR was performed using the Ag-path-ID One-Step RT-PCR Kit using 20 microl reaction volumes and final primer and probe concentrations of 400 nM and 120 nM respectively. Cycling conditions were as above for tRNAlys3.
###end p 66
###begin p 67
###xml 92 100 92 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000231.s001">Table S1</xref>
All primer and probe sequences, as well as their respective amplicons, are also provided in Table S1.
###end p 67
###begin title 68
Immunoblot Analysis
###end title 68
###begin p 69
###xml 167 169 167 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA</sup>
###xml 108 113 <span type="species:ncbi:9606">Human</span>
###xml 232 237 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 325 331 <span type="species:ncbi:9986">rabbit</span>
###xml 485 489 <span type="species:ncbi:9925">Goat</span>
###xml 495 501 <span type="species:ncbi:9986">rabbit</span>
###xml 522 527 <span type="species:ncbi:10090">mouse</span>
Virions were concentrated by centrifugation through a 20% (w/v) sucrose cushion before immunoblot analysis. Human A3G protein, heat shock protein (HSP) 90 or viral p24CA proteins were detected in whole cell lysates of uninfected or HIV-1 infected CEM cells or transfected 293T cells, or in virion lysates, using a polyclonal rabbit serum to A3G, HSP 90alpha  beta (H-114, Santa Cruz Biotechnology), or 24-2, a monoclonal anti-CA antibody, respectively, secondary antibodies IRDye800CW Goat Anti-rabbit and IRDye800CW Anti-mouse (LI-COR Biosciences UK Ltd) and Li-cor Odyssey infrared imaging and quantitation.
###end p 69
###begin title 70
Supporting Information
###end title 70
###begin p 71
Names and sequences of qPCR primers and probes used.
###end p 71
###begin p 72
(0.04 MB PDF)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin title 74
References
###end title 74
###begin article-title 75
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
###end article-title 75
###begin article-title 76
The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.
###end article-title 76
###begin article-title 77
APOBEC-mediated viral restriction: not simply editing?
###end article-title 77
###begin article-title 78
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 accessory proteins-Ensuring viral survival in a hostile environment.
###end article-title 78
###begin article-title 79
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
###end article-title 79
###begin article-title 80
Single-stranded RNA facilitates nucelocapsid:APOBEC3G complex formation.
###end article-title 80
###begin article-title 81
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
###end article-title 81
###begin article-title 82
###xml 48 51 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 74 77 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.
###end article-title 82
###begin article-title 83
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
###end article-title 83
###begin article-title 84
DNA deamination mediates innate immunity to retroviral infection.
###end article-title 84
###begin article-title 85
###xml 32 37 <span type="species:ncbi:9606">human</span>
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
###end article-title 85
###begin article-title 86
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
###end article-title 86
###begin article-title 87
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
###end article-title 87
###begin article-title 88
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
###end article-title 88
###begin article-title 89
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G.
###end article-title 89
###begin article-title 90
###xml 42 77 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
###end article-title 90
###begin article-title 91
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.
###end article-title 91
###begin article-title 92
###xml 25 30 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells.
###end article-title 92
###begin article-title 93
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 76 111 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Inhibition of tRNAlys-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
###end article-title 93
###begin article-title 94
###xml 56 91 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
###end article-title 94
###begin article-title 95
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1.
###end article-title 95
###begin article-title 96
###xml 34 56 <span type="species:ncbi:272636">adeno-associated virus</span>
APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.
###end article-title 96
###begin article-title 97
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
APOBEC3 inhibits mouse mammary tumour virus replication in vivo.
###end article-title 97
###begin article-title 98
###xml 14 31 <span type="species:ncbi:10407">hepatitis B virus</span>
Inhibition of hepatitis B virus replication by APOBEC3G.
###end article-title 98
###begin article-title 99
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
###end article-title 99
###begin article-title 100
Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.
###end article-title 100
###begin article-title 101
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
###end article-title 101
###begin article-title 102
###xml 64 69 <span type="species:ncbi:9606">human</span>
Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect.
###end article-title 102
###begin article-title 103
###xml 83 86 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
###end article-title 103
###begin article-title 104
APOBEC3G DNA deaminase acts processively 3'-->5' on single-stranded DNA.
###end article-title 104
###begin article-title 105
###xml 33 68 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA.
###end article-title 105
###begin article-title 106
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.
###end article-title 106
###begin article-title 107
###xml 38 55 <span type="species:ncbi:10407">hepatitis B virus</span>
Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G.
###end article-title 107
###begin article-title 108
APOBEC-mediated interference with hepadnavirus production.
###end article-title 108
###begin article-title 109
Cytidine deamination of retroviral DNA by diverse APOBEC proteins.
###end article-title 109
###begin article-title 110
T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity.
###end article-title 110
###begin article-title 111
###xml 82 98 <span type="species:ncbi:11955">avian retrovirus</span>
Two species of full-length cDNA are synthesized in high yield by melittin-treated avian retrovirus particles.
###end article-title 111
###begin article-title 112
###xml 36 71 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: An important stage for viral infection of nondividing cells.
###end article-title 112
###begin article-title 113
###xml 51 56 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.
###end article-title 113
###begin article-title 114
###xml 32 67 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Role of Vif in stability of the human immunodeficiency virus type 1 core.
###end article-title 114
###begin article-title 115
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
###end article-title 115
###begin article-title 116
###xml 79 84 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif.
###end article-title 116
###begin article-title 117
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 replication and regulation of APOBEC3G by peptidyl prolyl isomerase Pin1.
###end article-title 117
###begin article-title 118
###xml 76 111 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps.
###end article-title 118
###begin article-title 119
###xml 4 39 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes.
###end article-title 119
###begin article-title 120
###xml 107 142 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1.
###end article-title 120
###begin article-title 121
###xml 19 54 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.
###end article-title 121
###begin article-title 122
###xml 53 58 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 62 67 <span type="species:ncbi:9606">human</span>
Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F.
###end article-title 122
###begin article-title 123
Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins.
###end article-title 123
###begin article-title 124
###xml 89 94 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions.
###end article-title 124
###begin article-title 125
Complementary function of the two catalytic domains of APOBEC3G.
###end article-title 125
###begin article-title 126
7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G.
###end article-title 126
###begin article-title 127
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Hypermutation of HIV-1 DNA in the absence of the Vif protein.
###end article-title 127
###begin article-title 128
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
###xml 109 116 <span type="species:ncbi:9606">patient</span>
Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells.
###end article-title 128
###begin article-title 129
###xml 69 104 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo.
###end article-title 129
###begin article-title 130
###xml 27 62 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
G-->A hypermutation of the human immunodeficiency virus type 1 genome: Evidence for dCTP pool imbalance during reverse transcription.
###end article-title 130
###begin article-title 131
###xml 181 216 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Comparison of G-to-A mutation frequencies induced by APOBEC3 proteins in H9 cells and peripheral blood mononuclear cells in the context of impaired processivities of drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.
###end article-title 131
###begin article-title 132
###xml 70 105 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.
###end article-title 132
###begin article-title 133
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 76 111 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.
###end article-title 133
###begin article-title 134
###xml 23 58 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
###end article-title 134
###begin p 135
The authors have declared that no competing interests exist.
###end p 135
###begin p 136
This study was supported by the Royal Society, the United Kingdom Medical Research Council, and the National Institutes of Health (AI070072). KNB is a Royal Society Dorothy Hodgkin Research Fellow. MHM is an Elizabeth Glaser Scientist.
###end p 136

